The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 20, 2008
Filed:
Dec. 01, 1999
Julio César Aguilar Rubido, La Habana, CU;
Daniel O. Palenzuela Gardón, La Habana, CU;
Verena L. Muzio González, C. Habana, CU;
Gerardo E. Guillén Nieto, C. Habana, CU;
Eduardo Pentón Arias, C. Habana, CU;
Dagmara Pichardo Díaz, C. Habana, CU;
Enrique Iglesias Perez, C. Habana, CU;
Julio César Aguilar Rubido, La Habana, CU;
Daniel O. Palenzuela Gardón, La Habana, CU;
Verena L. Muzio González, C. Habana, CU;
Gerardo E. Guillén Nieto, C. Habana, CU;
Eduardo Pentón Arias, C. Habana, CU;
Dagmara Pichardo Díaz, C. Habana, CU;
Enrique Iglesias Perez, C. Habana, CU;
Centro de Ingenieria Genetic y Biotechnologia, Ciudad de la Habana, CU;
Abstract
The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation. These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced. The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.